Cargando…

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies

PURPOSE: Rescue medication use is common in chronic obstructive pulmonary disease (COPD) patients and tends to increase with symptoms and disease severity. An analysis of baseline rescue medication use was conducted to inform on patient phenotypes and subsequent effects on lung function, symptoms, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donohue, James F, Ozol-Godfrey, Ayca, Goodin, Thomas, Sanjar, Shahin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166066/ https://www.ncbi.nlm.nih.gov/pubmed/32341641 http://dx.doi.org/10.2147/COPD.S242767

Ejemplares similares

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
por: Putcha, Nirupama, et al.
Publicado: (2021)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Ohar, Jill A, et al.
Publicado: (2020)

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Tashkin, Donald P, et al.
Publicado: (2021)

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
por: Ohar, Jill, et al.
Publicado: (2018)

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
por: Hanania, Nicola A, et al.
Publicado: (2021)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies
por: Ohar, Jill A, et al.
Publicado: (2019)

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021)

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD
por: Siler, Thomas M., et al.
Publicado: (2021)

Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies
por: Tashkin, Donald P., et al.
Publicado: (2019)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]
Publicado: (2020)

Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
por: Kerwin, Edward M, et al.
Publicado: (2018)

Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
por: Donohue, James F., et al.
Publicado: (2017)

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
por: Ohar, Jill A., et al.
Publicado: (2020)

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
por: Pham, Stephen, et al.
Publicado: (2018)

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease
por: Leaker, Brian R, et al.
Publicado: (2015)

Nebulized formoterol: a review of clinical efficacy and safety in COPD
por: Gross, Nicholas J, et al.
Publicado: (2010)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
Publicado: (2021)

Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease
por: Leaker, Brian R., et al.
Publicado: (2019)

Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease
por: Santus, Pierachille, et al.
Publicado: (2017)

Can glycopyrrolate come to the airway rescue in Covid-19 patients?
por: Garg, Heena
Publicado: (2020)

Efficacy of Glycopyrrolate in Primary Hyperhidrosis Patients
por: Lee, Hyun Ho, et al.
Publicado: (2012)

Evaluation of efficacy and safety of glycopyrrolate - xylazine - propofol anesthesia in buffalo calves
por: Potliya, Sandeep, et al.
Publicado: (2015)

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study
por: LaForce, Craig, et al.
Publicado: (2016)

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
por: Wang, Chen, et al.
Publicado: (2020)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
por: Pleasants, Roy A.
Publicado: (2018)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

1054 Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age
por: Gorse, Geoffrey J., et al.
Publicado: (2014)

A comparative study of efficacy and safety of arformoterol and salbutamol nebulization as rescue therapy in acute non-severe asthma
por: Das, Sibes K., et al.
Publicado: (2011)

Is nebulized saline a placebo in COPD?
por: Khan, Shahina Y, et al.
Publicado: (2004)

Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
por: Ganapathy, Vaidyanathan, et al.
Publicado: (2017)

Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD
por: Reisner, Colin, et al.
Publicado: (2018)

Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD
por: Chen, Rongchang, et al.
Publicado: (2020)

Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD
por: Ichinose, Masakazu, et al.
Publicado: (2019)

Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study
por: Kerwin, Edward M., et al.
Publicado: (2019)

Nebulized corticosteroids in the management of acute exacerbation of COPD
por: Gaude, G. S., et al.
Publicado: (2010)

A review of nebulized drug delivery in COPD
por: Tashkin, Donald P
Publicado: (2016)

Effectiveness of treatment with nebulized colistin in patients with COPD
por: Bruguera-Avila, Nuria, et al.
Publicado: (2017)

Nebulized Therapies in COPD: Past, Present, and the Future
por: Barjaktarevic, Igor Z, et al.
Publicado: (2020)

Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies
por: Kerwin, Edward M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dhmejsl9isf3ss764mstr4in2i